Business
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung
About this update from Moderna, Inc.
[{"type":"text","content":"Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung deliveryModerna's 5th Annual Science and Technology Day presentations highlight continued focus, safety and innovation of our intramuscular lipid nanoparticles (LNPs) delivery system in vaccinesCAMBRIDGE, MA / ACCESSWIRE / May 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new research findings as part of the Company's fifth annual Science and Technology Day. Moderna continues to highlight investments in the expansion of the utility of the mRNA platform, characterization of the Company's vaccines, biodistribution of vaccines, and using clinical data to predict vaccine dosing.\"Science and Technology Day gives us an opportunity to showcase our leadership in mRNA medicines. Having continuously invested in our mRNA platform for more than 10 years, Moderna is well-positioned to continue bringing innovative medicines to the world through next-generation technology, research and manufacturing. I'm particularly excited about the advances that our more than 700 experienced platform research scientists have made in delivering medicines to the lungs and intramuscularly for vaccines, and am confident that the financial resources and expertise Moderna has will ensure Moderna remains as the world leader in mRNA,\" said Stéphane Bancel, Chief Executive Officer of Moderna.Expansion of the utility of the mRNA platformMultiple biological barriers must be overcome to deliver mRNA medicines and maximize their clinical potential. In most cases, the effective delivery of mRNA-based medicines is enabled by encapsulating the mRNA in tiny lipid (fat) droplets, known as lipid nanoparticles (LNPs) in order to protect it against degradation and facilitate uptake by cells. Moderna announces advances in developing numerous proprietary LNPs, each suited to target different cell types and optimized for different routes of administration. Moderna has invested in the development of LNPs for systemic, intramuscular, intratumoral, and pulmonary delivery of mRNA.With Moderna's focus on respiratory diseases, the Company has invested in designing mRNA delivery systems tailored to targeting pulmonary disease. For pulmonary appl...